Predominantly, the participants experienced gastrointestinal side effects with Tirzepatide (more incidence with higher doses) - being similar to GLP-1 RAs, with a small number proportion experiencing hypoglycemia (3%), or AEs leading to discontinuation of therapy (7%). Here, GLP1R is linked to Hypoglycemia.